Hematology Frontier

From September 13th to 17th, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the world's top oncology conferences, it brought together experts and scholars from across the globe to share cutting-edge research findings and discuss future directions. At the session dedicated to hematologic malignancies, Dr. Junyuan Qi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented the first-in-human study of the BCL-2 inhibitor TQB3909 in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML), showing promising results. Hematology Frontier invited Professor Qi to provide an in-depth analysis of the study and discuss the future clinical applications and research directions for this novel BCL-2 inhibitor.

From September 25-29, 2024, the "27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting," hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, will be held in Xiamen. The conference, themed "Patient-Centered, Sharing the Future," brings together the latest research advancements and developments in the field, both domestically and internationally. For more than 20 years, CSCO has been at the forefront of clinical oncology in China, with experts deeply involved in its growth, advancing their careers through this platform. Hematology Frontier has launched a special "Growing with CSCO" series, inviting Chinese scholars to revisit past stories. In this issue, we invited Dr. Ou Bai, a member of the CSCO United Committee for Lymphoma Intervention (UCLI) and a key figure in the development of the lymphoma specialty at The First Bethune Hospital of Jilin University, to share the story of growing together with CSCO.

From September 13 to 17, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the world's leading oncology events, experts and scholars from across the globe gathered to share cutting-edge research results and explore future development directions. In the Mini Oral session on hematologic malignancies, Dr. Zhiming Li from the Sun Yat-sen University Cancer Center presented the results of a phase I/II study on the combination of chidamide and mitoxantrone hydrochloride liposome in the treatment of relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This study offers new options to improve the prognosis of R/R PTCL patients and contributes a promising Chinese strategy to the global development of hematologic oncology. Hematology Frontier invited Professor Li to provide an in-depth analysis of the study and share his expectations for future research on this combination therapy.

From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was grandly held, attracting global experts to foster academic exchange and cooperation. During the conference, Hematology Frontier invited Dr. Peiqi Zhao from Tianjin Medical University Cancer Institute and Hospital to discuss the latest advances in follicular lymphoma treatment and the evolving concept of comprehensive disease management.

The 5th Tianjin International Lymphoma Conference was successfully held from September 6 to 8, 2024. The conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, providing a platform for international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Xiubao Ren from Tianjin Medical University Cancer Institute and Hospital to share insights on the progress of clinical trials in reverse immune editing therapy and its future application prospects in cancer treatment.

From September 13 to 17, 2024, the European Society for Medical Oncology (ESMO) Annual Meeting is being held in Barcelona, Spain. As one of the top international oncology conferences, the event gathers experts and scholars from around the world to share cutting-edge research and discuss future developments. In the Mini Oral Session on Hematologic Malignancies, Dr. Ling Pan from West China Hospital, Sichuan University, presented a pivotal phase II study comparing rovatirelinib with hydroxyurea for the treatment of intermediate and high-risk myelofibrosis (MF). The results demonstrated significant benefits in both efficacy and safety for rovatirelinib, offering a new potential treatment option for MF patients. Hematology Frontier invited Dr. Ling Pan to discuss the current landscape and challenges in the diagnosis and treatment of MF, provide insights into this pivotal study, and share her experiences at the ESMO conference.

The treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has always been a significant challenge and a hot topic in the field of hematologic malignancies. For these patients, treatment options are extremely limited after multiple lines of therapy. Their salvage therapy has a low remission rate and short survival time. Currently, there is an urgent need for new effective treatment regimens to improve patient outcomes. The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) was held in Houston, USA, from September 4th to 7th, 2024, bringing together top experts in the field of hematologic malignancies worldwide to exchange the latest research findings and discuss new therapeutic strategies. During the conference, Dr. Christopher A. Yasenchak from the Willamette Valley Cancer Institute and Rsearch Center was selected for an oral presentation titled 'Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study' (Abstract Number: ABCL-711). Hematology Frontier specially invited Professor Christopher A. Yasenchak to interpret the efficacy and clinical significance of the BV+R2 (Brentuximab Vedotin combined with Rituximab and Lenalidomide) regimen in the ECHELON-3 study.

The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4th to 7th, 2024, gathering top experts in the field of hematologic malignancies from around the world to exchange the latest research findings and discuss new therapeutic strategies. At the conference, Dr. Eunice Wang from the Roswell Park Comprehensive Cancer Center in the United States presented the latest developments in the research and development of Menin inhibitors. For this, 'Oncology Frontier - Hematology Frontier' specially interviewed Dr. Eunice Wang and provided a wonderful interpretation around this topic.

From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was successfully held. The conference featured 12 specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform that fosters international academic exchange and cooperation. During the event, Hematology Frontier had the privilege of interviewing the conference chair, Dr. Huilai Zhang from Tianjin Medical University Cancer Institute & Hospital. He shared insights into the highlights of the conference and the future development of lymphoma research.

In the field of hematopoietic stem cell transplantation (HSCT), immunomodulatory mechanisms play a crucial role, affecting not only the success rate of the transplant but also the recipient's tolerance to the graft and their long-term health post-transplant. At the 12th Lu Daopei Hematology Academic Forum, Dr. Robert Negrin, former Chief of the Blood and Marrow Transplantation at Stanford University, shared a fascinating lecture on immunomodulatory mechanisms and transplantation. "Hematology Frontier" specially invited Dr. Robert Negrin for an exclusive interview, providing us with an international perspective on cutting-edge topics such as graft-versus-host disease (GVHD), graft-versus-tumor effect (GVT), and immune tolerance.